This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
The only peptide that enhances sexual desire at the neurological level — not vascular. PT-141 activates melanocortin receptors in the brain to directly increase libido and arousal in both men and women. FDA-approved molecule.
PT-141 (bremelanotide) is a synthetic melanocortin peptide derived from Melanotan II. Unlike PDE5 inhibitors (sildenafil, tadalafil) that work through peripheral vascular mechanisms, PT-141 acts centrally in the brain — specifically activating MC3R and MC4R melanocortin receptors in the hypothalamus, which are directly involved in the neural circuitry of sexual desire and arousal.
The downstream effect of melanocortin receptor activation is dopamine pathway stimulation — the same neurological pathway associated with motivation, reward, and sexual interest. This is why PT-141 increases the *desire* for sex rather than just producing a mechanical vascular response. It is the only FDA-approved peptide targeting this mechanism, approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019.
For men, PT-141 enhances sexual desire and has been shown to produce penile erections through central (not peripheral) pathways — complementing rather than replacing PDE5 inhibitors in men who have desire but vascular insufficiency. For women, it addresses the most common form of female sexual dysfunction: loss of interest in sex regardless of relationship quality or psychological factors.
PT-141 works in the hypothalamus, not the blood vessels. It activates the dopamine pathways that generate sexual interest — increasing genuine desire rather than just physiological response.
The only FDA-approved medication specifically for hypoactive sexual desire disorder (HSDD) in women. Clinical trials showed significant improvement in satisfying sexual events and desire scores.
Shown to produce erections in men through central pathway activation — and enhances desire independent of mechanical function, making it complementary to PDE5 inhibitors in men with desire deficits.
Subcutaneous injection produces effects within 45–90 minutes, lasting approximately 4–6 hours. Planned administration removes the spontaneity issue associated with some treatments.
Bremelanotide received FDA approval in 2019 — establishing a clinical safety database including Phase 2 and Phase 3 human trial data across multiple populations.
PT-141 does not require sexual stimulation to initiate desire — it creates the neurological state of wanting rather than just responding to stimulation, which is the core unmet need for HSDD.
PT-141 is administered subcutaneously 45–90 minutes before the desired effect. The FDA-approved Vyleesi dose is 1.75 mg. Research community protocols typically range from 1.0–2.0 mg, with individual response varying significantly.
Nausea is the most common side effect and is dose-dependent — starting at 1.0 mg and adjusting based on response is the standard approach. Flushing, headache, and mild blood pressure elevation are also reported.
| Parameter | Detail |
|---|---|
| Starting Dose | 1.0 mg SC (adjust to response) |
| Standard Dose | 1.75 mg SC (FDA-approved dose) |
| Timing | 45–90 minutes before desired effect |
| Frequency | As needed; not more than once per 24 hours |
| Route | Subcutaneous — abdomen or thigh |
| Duration of Effect | Approximately 4–6 hours |
PDE5 inhibitors (Viagra, Cialis) work peripherally — they increase blood flow to genital tissue. PT-141 works centrally — it changes how the brain generates sexual desire through dopamine pathways. The two mechanisms are complementary: PT-141 addresses desire, PDE5 inhibitors address mechanical function. Many users who don't respond to PDE5 inhibitors because of desire deficits (rather than vascular issues) find PT-141 more directly relevant.
Yes — and it has the clinical trial data to prove it. Bremelanotide was FDA-approved specifically for HSDD in premenopausal women. The RECONNECT Phase 3 trials showed statistically significant increases in satisfying sexual events and desire scores versus placebo in women with acquired, generalized HSDD.
Nausea is the most common (40% in FDA trials), typically mild and resolving within 2 hours. Flushing (face warmth/redness), headache, and mild blood pressure increase are also reported. Nausea is dose-dependent — starting at 1.0 mg reduces incidence significantly. Taking with food or an anti-nausea medication before injection can help.
PT-141 causes transient blood pressure increases and should be avoided by individuals with cardiovascular disease, uncontrolled hypertension, or those taking medications that affect blood pressure. It is not recommended during pregnancy. Consult a healthcare professional before use, particularly if any cardiovascular risk factors are present.
PT-141 is sold for research purposes only. While bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women, research peptide PT-141 is not a pharmaceutical drug and should not substitute for physician-prescribed treatment. Consult a qualified healthcare professional before use. Not for use in individuals with cardiovascular disease or uncontrolled hypertension.
Third-party tested PT-141 with Finnrick Analytics verification. Full COA on every batch. Ships within 24 hours.
Get Started TodayMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.